Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)

Conclusions:
In PCa patients who failed LHRH therapy, degarelix was well tolerated and achieved a limited PSA response. Phase III trials show that disease control benefits with degarelix versus agonists are more clearly demonstrated as first-line therapy.

Source: Therapeutic Advances in Urology - May 25, 2015 Category: Urology & Nephrology Authors: Miller, K., Simson, G., Goble, S., Persson, B.-E. Tags: Original Research Source Type: research